{"id":10603,"date":"2026-08-02T14:46:27","date_gmt":"2026-08-02T09:16:27","guid":{"rendered":"https:\/\/chiralpedia.com\/blog\/?p=10603"},"modified":"2026-08-02T14:47:00","modified_gmt":"2026-08-02T09:17:00","slug":"why-chirality-still-matters-in-pharmaceutical-analysis","status":"publish","type":"post","link":"https:\/\/chiralpedia.com\/blog\/why-chirality-still-matters-in-pharmaceutical-analysis\/","title":{"rendered":"Episode 1: Why Chirality Still Matters: Stereochemistry as a Critical Quality Attribute"},"content":{"rendered":"\n

The pharmaceutical meaning of chirality, the real impurity space, and where chiral HPLC fits<\/em><\/p>\n\n\n\n

The pharmaceutical meaning of chirality<\/strong><\/p>\n\n\n\n

Chirality matters in drug development for a simple reason. Biological systems are chiral, so the body does not experience two stereoisomers as the same molecule. FDA stated this explicitly in its landmark 1992 stereoisomer guidance, noting that enantiomers may differ in pharmacokinetics and in pharmacologic or toxicologic effects, and that modern technology removed the old practical excuse that racemates were easier to make than single enantiomers. EMA\u2019s long-standing chirality guidance makes the same point from a development perspective, requiring explicit consideration of chiral active substances and their stereochemical behaviour during medicinal product development. [1,2] <\/p>\n\n\n\n

That scientific reality has not become less important with time. A recent perspective on new drug approvals from 2013 to 2022 showed that chirality still strongly shapes the approved small-molecule landscape, with regulatory and industrial preference continuing to favour single-enantiomer products in many settings. The same literature also highlights growing attention to atropisomerism, especially in modern medicinal chemistry. [3,4] <\/p>\n\n\n\n

For the analytical scientist, chirality is therefore not a decorative structural feature. It is a potential critical quality attribute. <\/mark>If the wrong stereoisomer changes potency, safety margin, disposition, or degradant behaviour, then stereochemical composition has to be measured, understood, and controlled with the same seriousness as any other clinically relevant impurity profile. FDA\u2019s stereoisomer guidance, EMA\u2019s chirality note, and ICH Q6A all point in that direction. [1,2,5]<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

What counts as a stereochemical impurity<\/strong><\/p>\n\n\n\n

In routine discussion, “chiral impurity” usually means the opposite enantiomer of a single-enantiomer API. That use is too narrow. The practical impurity space is broader:<\/p>\n\n\n\n

Stereochemically altered degradation products<\/strong> formed by racemisation or epimerisation during synthesis, isolation, formulation, or storage.<\/p>\n\n\n\n